Mirum Group company information, Employees & Contact Information

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Purpose, not just product: What sets Mirum apart Endpoints News

Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) Seeking Alpha

US FDA approves Mirum Pharma's genetic disorder drug Reuters

The Mirum Moto Jacket is the Fruit of Another Tomorrow’s Graveyard Diligence Sourcing Journal

Mirum-maker Natural Fiber Welding to ‘wind down’ operations Just Style

After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder Fierce Pharma

Mirum plans 2025 Phase 2 trial testing fragile X treatment Fragile X News Today

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study Business Wire

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Yahoo Finance

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) Seeking Alpha

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire

MCM launches debut leather alternative collection featuring Mirum fashionunited.uk

Mirum reports findings from Phase II biliary atresia therapy trial Clinical Trials Arena

Mirum Gains 35% in 3 Months: How Should You Play the Stock? Yahoo Finance

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer Business Wire

Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations Yahoo Finance

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Business Wire

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates Yahoo Finance

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities Seeking Alpha

Mirum snaps up 2 liver disease drugs from Travere for up to $445M Fierce Pharma

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (MIRM) Seeking Alpha

Mirum scores 2nd FDA nod for rare liver disease drug Livmarli, this one to treat PFIC Fierce Pharma

The men behind Mirum India launch age-tech startup Campaign India

Mirum and Tencel as alternative leather Innovation in Textiles

Mirum blames enrollment woes for halting phase 2 trial for pregnancy liver disorder Fierce Biotech

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis BioSpace

Market verdicts: is NFW with Mirum really at the end of the road? La conceria.it | Il portale dell'area pelle

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC Business Wire

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation Business Wire

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics Business Wire

Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering Business Wire

Natural Fiber Welding: “Mirum Will be the Standard in Vegan Leather – a Standard Where Vegan Will Mean Plants and Never Plastic.” vegconomist

Shire Licenses Rare Liver Disease Candidates to $120M Startup Mirum Genetic Engineering and Biotechnology News

Resort Development Spotlight: Luxury mixed-use project Elounda Hills by Mirum Group Hospitality Investor

Introducing Mirum: A Modern Global Company WPP

Beej brings plastic-free leather alternative Mirum to India FashionNetwork India

JWT confirms restructure of Mirum Singapore Marketing-Interactive

Twist Image to become Mirum strategyonline.ca